Fibrino 500 mg (Capsule)

Unit Price: ৳ 23.00 (3 x 6: ৳ 414.00)
Strip Price: ৳ 138.00

Medicine Details

Category Details
Generic Tranexamic acid
Company Eskayef pharmaceuticals ltd
Also available as
Fibrino 500 mg injection

Title

  • Fibrino Tablet 500mg
  • Antihemorrhagic Medication

Categories

  • Medicine
  • Health & Wellness
  • Pharmaceuticals

Description

  • Prophylaxis and therapy of hemophtoes, digestive hemorrhages, hemorrhagic syndromes
  • Prevents post-partum and puerperium hemorrhages
  • Inhibits bleeding during surgical interventions
  • Suitable for various medical specialties like surgery, urology, obstetrics, otorhinolaryngology
  • Also used in stomatology, oncology, and as supportive therapy in oncology
  • Contains tranexamic acid with strong antifibrinolytic action
  • Exhibits almost non-existent chronic toxicity and extremely low acute toxicity
  • Well absorbed by oral route and excreted mainly by renal route
  • Does not interfere with clotting processes or cause thrombophilia
  • Recommended adult dosage: 500-1000 mg 3 times daily
  • Recommended children's dosage for prophylaxis and therapeutic purposes
  • No reduction in dosage necessary for elderly patients unless there is evidence of renal failure
  • Incompatible with solutions containing penicillins, thrombolytic drugs like Streptokinase & Urokinase
  • Potential for thrombus formation may increase with concomitant administration of estrogen-containing drugs
  • Known contraindications include individual hypersensitivity, thromboembolic disease, serious kidney failure
  • Possible side effects include sense of fatigue, conjunctival irritation, nausea, diarrhea, postural hypotension
  • Should not be administered during known and presumed pregnancy, passes into breast milk in low concentration
  • Precautions include careful use in cases of hyperfibrinolysis, serious renal insufficiency, cardiopathic and hepatopathic subjects
  • Belongs to therapeutic classes of anti-fibrinolytic drugs and haemostatic drugs
  • Storage conditions: Store in a dry place at 15-30°C, away from light and keep out of children's reach

Dimensions

N/A

Color Options

N/A

Functions

  • Prophylaxis
  • Therapy of hemorrhagic manifestations
  • Antihemorrhagic therapy during operations of any type and nature
  • Inhibition of the plasminogen activation of both exogenous and endogenous activators
  • Promotes the formation of a fibrin capsule to inhibit the growth of ovarian tumors
  • Reduces bleeding during surgical interventions

Materials

  • Tranexamic acid (trans-4 aminomethyl-cyclohexanecarboxylic acid)

Technical Specifications

  • Antifibrinolytic Action: 10 times more active than conventional hemostatics
  • Toxicity: Extremely low acute toxicity, almost non-existent chronic toxicity
  • Absorption: Well absorbed by oral route
  • Excretion: Mainly by renal route
  • Dosage Forms: Tablets and parenteral (intravenous or intramuscular) route
  • Onset of Effect: 15-30 minutes after oral administration
  • Dosage for Children: Varies based on body weight and route of administration

Design Elements

N/A

Usability Features

  • Suitable for use in various medical specialties
  • Suitable for adult, children, and elderly patients
  • Easy oral administration
  • Suitable for parenteral administration
  • Long-lasting antifibrinolytic effect

Interaction

  • Incompatible with: Solutions containing penicillins, thrombolytic drugs like Streptokinase & Urokinase
  • Increased Thrombus Formation with: Concomitant administration of estrogen-containing drugs

Contraindications

  • Individual hypersensitivity to the product
  • Thromboembolic disease
  • Arterial and venous thrombosis
  • Endocavitary hemorrhages
  • Serious kidney failure

Side Effects

  • Sense of fatigue
  • Conjunctival irritation
  • Nasal blockage
  • Itching
  • Skin reddening
  • Exanthems
  • Nausea
  • Diarrhea
  • Gastric pyrosis
  • Postural hypotension

Pregnancy & Lactation

  • Pregnancy: Should not be administered during known and presumed pregnancy
  • Lactation: Passes into breast milk in low concentration, unlikely antifibrinolytic effect in the infant

Precautions & Warnings

  • Use in hyperfibrinolysis cases
  • Begin prophylactic treatment 24 hours before operation and continue until 3-4 days after
  • Prolong therapy of hemorrhages for at least 24 hours after manifestations have disappeared
  • Reduce doses in hematuria to prevent formation of clots in the urinary tract
  • Avoid use in serious renal insufficiency or anuric syndromes
  • Use with caution in less serious renal dysfunctions
  • Requires particular care in cardiopathic and hepatopathic subjects

Therapeutic Class

  • Anti-fibrinolytic drugs
  • Haemostatic drugs

Storage Conditions

Store in a dry place at 15-30°C, away from light and keep out of children's reach

Related Brands